Active Studies

The primary purpose of this study is to determine if MLN0128 in combination with weekly
paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.

The purpose of this study is to identify the optimal dosing strategy for low-dose ketamine
infusions in adult acute burn injury patients when used with usual pain medications.

This study compares EG-1962 to enteral nimodipine in the treatment of aneurysmal
subarachnoid hemorrhage.

This trial will consist of three arms: Part A, Part B, and Part C. Part A has two groups.
The first group will enroll adult subjects with cystic fibrosis (CF) into a single ascending
dose (SAD) treatment group. The second group will enroll adult subjects with CF, including
those on background treatment with ORKAMBI® and those not on a cystic fibrosis transmembrane
conductance regulator (CFTR) modulator, into a multiple ascending dose (MAD) treatment
group. Part B will enroll adult subjects with CF currently on stable ORKAMBI® background
therapy for a minimum of 3 months into a Phase II treatment group consisting of two cohorts.
Part C will enroll adult subjects with CF, including those on background treatment with
KALYDECO® and those not on a CFTR modulator, into a Phase II treatment group consisting of
three cohorts. Approximately 136 subjects will be enrolled.

Pages